AURORA, CO, May 13, 2004 – GlobeImmune, Inc. today announced that Teresa Brentnall, MD, Edgar Engleman, MD, Edward Mocarski, PhD, Alan Venook, MD, and Bruce Walker, MD have been appointed to the company’s Scientific Advisory Board.
“These outstanding professionals in the scientific and medical community bring valuable insights and decades of experience” said Dr. Timothy Rodell, CEO of GlobeImmune. “Bringing the expertise of these new Advisors to our product development efforts will strengthen GlobeImmune’s ability to move new immunotherapies into and through clinical trials.”
Dr. Brentnall is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Washington School of Medicine where she directs the molecular laboratory for the Division of Gastroenterology research group. Dr. Brentnall received her degree from the University of Washington School of Medicine, completed a residency in Internal Medicine at the University of California, Los Angeles, and then took a combined gastroenterology-molecular genetics fellowship at the University of Washington. Currently Dr. Brentnall studies colon cancer, including how colon cancer forms in the setting of chronic inflammation, and pancreatic cancer. Her primary research area is investigation of molecular underpinnings and the natural history of neoplastic progression in pancreatic cancer, with a focus on early detection, gene discovery, and genetic/environmental underpinnings.
Dr. Engleman is Professor of Pathology and Medicine at the Stanford University School of Medicine where he has been for 26 years. His research laboratory is focused on the discovery of novel immunotherapeutic approaches to cancer and autoimmune diseases with the ultimate goal of treating disease by manipulating the immune system, in vivo. His group has studied human mononuclear leukocytes and their products and were the first to show that antigen pulsed dendritic cells can induce anti-tumor immunity in patients with cancer. He received his Bachelor’s degree from Harvard University and his M.D. from Columbia University School of Medicine. He has authored more than 250 publications and has been an editor of multiple journals.
Dr. Mocarski is Professor, Microbiology and Immunology, Stanford University School of Medicine where he has been on the faculty for 21 years and a tenured professor since 1989. His research focuses on the biology and pathogenesis of herpesviruses, with particular emphasis on cytomegalovirus, an important opportunistic pathogen. Dr. Mocarski’s work in this area has lead to important insights into the viral gene products that control productive replication, and he was the first to describe genetic engineering of herpesviruses and the identification the herpes simplex virus origin of DNA replication and genome packaging signals. Dr. Mocarski, a regular member of NIH NIAID and NHLBI review and workshop panels, is on the editorial boards of the Journal of Virology and Virology and has over 100 published articles on the subject of the biology, genetics, and pathogenesis of cytomegalovirus and herpesvirus.
Dr. Venook is an experienced and accomplished clinical investigator in the management of gastrointestinal malignancies. He is well known for his clinical research of new modalities to treat both primary and metastatic tumors of the liver and has led multiple cooperative group trials studying the use of chemotherapeutics in patients with liver disease. He is a Professor of Clinical Medicine at the University of California, San Francisco, where he leads the Gastrointestinal Oncology clinical program, the Hepatobiliary Program within the Comprehensive Cancer Center and is the Director of the UCSF / Mt. Zion Cancer Center Clinical Research Office. He sits on the Board of Directors of the Cancer and Leukemia Group B, and is also on the Editorial Board of the Journal of Clinical Oncology. He has published more than 50 original articles, chapters or books dealing with gastrointestinal malignancies.
Dr. Walker is Professor of Medicine and Director of the Division of AIDS at Harvard Medical School, and Director of the Partners AIDS Research Center at the Massachusetts General Hospital. He received his MD from Case Western Reserve University School of Medicine, and following an internship and residency in Internal Medicine at Massachusetts General Hospital and Harvard Medical School, completed a postdoctoral fellowship in infectious diseases, where he studied the cellular immune response to HIV in infected persons. Dr. Walker’s research focuses on cellular immune responses to HIV and hepatitis C virus (HCV), and he also continues his work as a clinician with a specialty in infectious diseases, focusing on the treatment of persons with HIV/AIDS. Dr. Walker was recently appointed as an investigator at the Howard Hughes Medical Institute.
About GlobeImmune
GlobeImmune, Inc. is an early-stage biopharmaceutical company developing potent, targeted molecular immunotherapies for the treatment of cancer and infectious diseases. The Company’s first two products for the treatment of cancers of the lung and gastrointestinal tract and the prevention and treatment of HIV/AIDS are expected to enter human clinical trials in 2004. For additional information, please visit the company’s website at https://globeimmune.com/. GlobeImmune is headquartered at the Fitzsimons BioScience Park in Aurora, Colorado.
Contact:
Timothy C. Rodell, MD CEO
GlobeImmune, Inc.
720-859-4070
